Recurrent visceral leishmaniasis in an immunocompetent patient: A case report

被引：8

作者：

Lagadinou M. ^{[1
]}

Dimitropoulou D. ^{[1
,2
]}

Assimakopoulos S.F. ^{[1
]}

Davoulos G. ^{[1
]}

Marangos M. ^{[1
,2
]}

机构：

[1] Department of Internal Medicine, University Hospital of Patras

[2] Division of Infectious Diseases, Department of Internal Medicine, University Hospital of Patras

来源：

Journal of Medical Case Reports | / 7卷 / 1期

关键词：

Immunocompetent; Leishmaniasis; Liposomal amphotericin B; Recurrent;

D O I：

10.1186/1752-1947-7-68

中图分类号：

学科分类号：

摘要：

Introduction. Current treatment options for visceral leishmaniasis (pentavalent antimony, amphotericin B, liposomal amphotericin B and mitelfosine) achieve long-term clinical cure in the majority of immunocompetent patients. Disease relapse is usually provoked by T-cell number or function impairment (corticosteroid or cytotoxic therapy, transplant recipients, advanced human immunodeficiency virus disease). Case presentation. We report a case of visceral leishmaniasis with multiple relapses in a 75-year-old Greek immunocompetent man. Visceral leishmaniasis relapses occurred despite appropriate treatment with liposomal amphotericin B 3mg/kg/day on days one to five, 14 and 21 (for the first episode and the first relapse) and mitelfosine 150mg/day for 28 days (for the second relapse). The third relapse was treated with high-dose liposomal amphotericin B (10mg/kg for two consecutive days), followed by a secondary prophylaxis of 3mg/kg once per month, which prevented disease reappearance during one year of follow-up. Conclusion: An unusual case of recurrent visceral leishmaniasis in an older immunocompetent patient was treated with high-dose liposomal amphotericin B and a monthly prophylaxis with no evidence of a relapse after one year of follow-up. © 2013 Lagadinou et al; licensee BioMed Central Ltd.

引用

共 15 条

[1]

Banuls A.L., Hide M., Prugnolle F., Leishmania and the leishmaniases: A parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans, Adv Parasitol, 64, pp. 1-109, (2007)

[2]

Herwaldt B.L., Leishmaniasis, Lancet, 354, 9185, pp. 1191-1199, (1999)

[3]

Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R.W., Alvar J., Boelaert M., Visceral leishmaniasis: What are the needs for diagnosis, treatment and control?, Nature Reviews Microbiology, 5, 11, pp. 873-882, (2007)

[4]

Weigle K., Saravia N.G., Natural history, clinical evolution, and the host-parasite interaction in new world cutaneous leishmaniasis, Clinics in Dermatology, 14, 5, pp. 433-450, (1996)

[5]

Desjeux P., The increase in risk factors for leishmaniasis worldwide, Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 3, pp. 239-243, (2001)

[6]

Murray H.W., Berman J.D., Davies C.R., Saravia N.G., Advances in leishmaniasis, Lancet, 366, 9496, pp. 1561-1577, (2005)

[7]

Okwor I., Uzonna J., Persistent parasites and immunologic memory in cutaneous leishmaniasis: Implications for vaccine designs and vaccination strategies, Immunol Res, 41, pp. 123-136, (2008)

[8]

Simon I., Wissing K.M., Del Marmol V., Antinori S., Remmelink M., Nilufer Broeders E., Nortier J.L., Corbellino M., Abramowicz D., Cascio A., Recurrent leishmaniasis in kidney transplant recipients: Report of 2 cases and systematic review of the literature, Transpl Infect Dis, 13, pp. 397-406, (2011)

[9]

Alvar J., Aparicio P., Aseffa A., Den Boer M., Canavate C., Dedet J.-P., Gradoni L., Ter Horst R., Lopez-Velez R., Moreno J., The relationship between leishmaniasis and AIDS: The second 10 years, Clinical Microbiology Reviews, 21, 2, pp. 334-359, (2008)

[10]

Colomba C., Scarlata F., Salsa L., Polara V.F., Titone L., La leishmaniosi viscerale nel bambino immunocompetente. Descrizione di due casi di recidiva dopo terapia specifica, Infezioni in Medicina, 12, 2, pp. 139-143, (2004)

← 1 2 →